iRefill app expands availability
NEWARK, N.J. —TeleManager, a pharmacy technology provider, announced last month that it made its iRefill application available for the Droid and Blackberry, in addition to the Microsoft and Apple platforms for which it already was available.
“The app allows smart phone users to order refills, pull up information about the pharmacy—such as its address, store hours and directions to the pharmacy, or even call the pharmacy—all from their iRefill app,” TeleManager co-founder and COO Paul Kobylevsky said.
The app has received positive reviews from users as well. “Not only are [customers] using it to request refills or call my pharmacy, but they [also] are showing their app to [friends] and colleagues,” said Craig McAlister, Conrad Marr Drug owner in Yukon, Okla.
‘Picture This’ forums bring diabetes management awareness to public
PRINCETON, N.J. A few days after it released a report on how awareness and education play an integral role in the prevention, detection and treatment of diabetes, Novo Nordisk is bringing it to the public.
The drug maker said Friday that, through its collaboration with the Entertainment Industries Council, it will host "Picture This" forums, which include an open discussion among diabetes stakeholders and the media to identify top diabetes communication challenges, explore strategies to address those priorities and strengthen community understanding about diabetes through news media and community affairs programs.
The forums will be held in Philadelphia on Oct. 22 and Seattle on Nov. 18.
"Novo Nordisk is proud to join EIC, the media and community leaders in Seattle and Philadelphia to explore ways to improve how diabetes is communicated about and understood by local citizens," said Tony Deluzio, senior medical director at Novo Nordisk. "As the prevalence of diabetes continues to be on the rise, bringing together those on the front line of diabetes care will open the potential to reduce the stigma associated with diabetes and empower those affected by the disease to lead full and productive lives."
Pfizer makes official tender offer for King
NEW YORK Pfizer officially has made its tender offer to buy King Pharmaceuticals for $3.6 billion, or $14.25 per share, Pfizer said Friday.
The offer constitutes a 40% premium over the closing price of King’s stock on Oct. 11, when Pfizer originally made the offer. King, based in Bristol, Tenn., specializes in pain medications designed to deter misuse and abuse, and Pfizer said the acquisition would enhance its position in the pain-relief market.
The offer expires at midnight on Nov. 19.